PRNewswire

Higher profit on improved gross margin and lower operating expenses

HONG KONG, May 21, 2024 /PRNewswire/ --

• Group revenue declined by 4.3% to US$2,145.7 million
• Gross profit margin improved from 28.3% to 29.6%
• Profit attributable to shareholders of the Company rose by 11.7% to US$166.6 million
• Final dividend of US48.0 cents per ordinary share, resulting in... (continue reading...)

BEIJING, May 21, 2024 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced that the Company's board of directors (the "Board") has approved a cash dividend of US$0.5700 per ADS (or US$0.1425 per ordinary share) payable in U.S. dollars (the "Dividend") to holders of ADSs and ordinary shares of record as of the close of business on July 10, 2024, New York... (continue reading...)

SINGAPORE, May 21, 2024 /PRNewswire/ -- OKX, a leading Web3 technology company, has issued updates for May 21, 2024.

OKX Launches 'OKX x MATR1X: Airdrop Pioneer Case NFT' Campaign Featuring 33,333 MATR1X Pioneer Souvenir Case NFTs

OKX today announced the launch of its 'OKX x MATR1X: Airdrop Pioneer Case NFT' campaign, giving the OKX Web3 community the... (continue reading...)

News provided by World News Media

LONDON, May 21, 2024 /PRNewswire/ -- Evgen Belousov, head of iGaming provider GR8 Tech, has been named Chief Executive Officer of the Year in the iGaming Industry by European CEO magazine.

Belousov launched GR8 Tech in January 2023, offering "tailored, flexible and scalable" sportsbook and casino platform and other products for operators in the iGaming industry. The company currently has clients in Africa, Asia and Europe, and... (continue reading...)

YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant progress of Telitacicept (RC18), that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren's syndrome (pSS) have completed patient enrollments.

Dr. Jianmin Fang, CEO of RemeGen, commented, "This marks further continued progress in RemeGen's... (continue reading...)